Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy

Iichiro Shimomura,1,4 Robert E. Hammer,2,4 James A. Richardson,3 Shinji Ikemoto,1 Yuriy Bashmakov,1 Joseph L. Goldstein,1,5 and Michael S. Brown1

1Department of Molecular Genetics, 2Department of Biochemistry and Howard Hughes Medical Institute, 3Department of Pathology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235 USA

Overexpression of the nuclear form of sterol regulatory element-binding protein-1c (nSREBP-1c/ADD1) in cultured 3T3-L1 preadipocytes was shown previously to promote adipocyte differentiation. Here, we produced transgenic mice that overexpress nSREBP-1c in adipose tissue under the control of the adipocyte-specific aP2 enhancer/promoter. A syndrome with the following features was observed: (1) Disordered differentiation of adipose tissue. White fat failed to differentiate fully, and the size of white fat depots was markedly decreased. Brown fat was hypertrophic and contained fat-laden cells resembling immature white fat. Levels of mRNA encoding adipocyte differentiation markers (C/EBPα, PPARγ, adipin, leptin, UCP1) were reduced, but levels of Pref-1 and TNFα were increased. (2) Marked insulin resistance with 60-fold elevation in plasma insulin. (3) Diabetes mellitus with elevated blood glucose (>300 mg/dl) that failed to decline when insulin was injected. (4) Fatty liver from birth and elevated plasma triglyceride levels later in life. These mice exhibit many of the features of congenital generalized lipodystrophy (CGL), an autosomal recessive disorder in humans.

[Key Words: SREBP, adipose tissue; diabetes mellitus; insulin resistance; congenital generalized lipodystrophy]

Received August 13, 1998; revised version accepted August 26, 1998.

Congenital generalized lipodystrophy (CGL) was delineated by Seip (1959) in studies of three children, two of whom were siblings. Subsequently, >100 patients with this developmental disorder have been described, and the syndrome has been well characterized clinically [Seip and Trygstad 1996]. Affected individuals are born with an extreme paucity of white fat, and they exhibit profound insulin resistance, hyperinsulinemia, hyperglycemia, an enlarged fatty liver, and varying degrees of hypertriglyceridemia. Secondary features include a voracious appetite, hypermetabolism, and an anabolic syndrome that includes organomegaly [pancreas, spleen, kidneys], rapid height development, and hypertrophy of skeletal and cardiac muscle. Inheritance is autosomal recessive. The underlying cause is unknown, and no mouse model has been developed. An understanding of the pathogenesis of this syndrome might provide insights into the much more common forms of insulin resistance that occur in obese individuals and lead to noninsulin-dependent diabetes mellitus.

One of the transcription factors that has been implicated in adipose differentiation is sterol regulatory element-binding protein-1c (SREBP-1c), one of three SREBPs found in animal cells [Tontonoz et al. 1993; Yokoyama et al. 1993]. The SREBP family of proteins was purified and cloned in our laboratory on the basis of their ability to bind and activate the promoters of genes involved in cholesterol biosynthesis and uptake [for review, see Brown and Goldstein 1997]. The SREBP-1c cDNA was isolated independently by Spiegelman and coworkers in an expression screen for proteins that bind to an E-box sequence in the promoter of fatty acid synthase [Tontonoz et al. 1993; Kim and Spiegelman 1996]. This cDNA was shown to exert effects on fatty acid synthesis and differentiation of mouse 3T3-L1 adipocytes in tissue culture, and, hence, the protein was named adipocyte determination and differentiation factor-1 (ADD-1).

The SREBPs are unique among transcription factors because they are synthesized as membrane-bound precursors. Each SREBP comprises ~1100 amino acids that are organized in three domains [Brown and Goldstein 1997]. The amino-terminal domain of ~500 amino acids is a transcription factor of the basic–helix–loop–helix leucine zipper family. This is followed by a membrane attachment domain and a carboxy-terminal regulatory domain. To activate transcription, the amino-terminal
domains of the SREBPs must be released from membranes of the endoplasmic reticulum (ER) so that they can enter the nucleus. Release is accomplished by two proteases that cut the SREBPs in obligatory order at site 1 and site 2. The site 1 protease is subject to feedback regulation by cholesterol. When cellular sterol levels are low, this protease is activated, and the amino-terminal domains enter the nucleus. When sterols accumulate in cells, the Site-1 protease is inactivated, and the SREBPs remain bound to extranuclear membranes. This control mechanism assures a constant supply of cholesterol and fatty acids while preventing overaccumulation.

The amino-terminal domains of the SREBPs (designated nSREBPs) are dual-specificity transcription factors that bind to nonpalindromic sterol regulatory elements as well as to palindromic E boxes (Yokoyama et al. 1993; Kim et al. 1995; Parraga et al. 1998). They turn on the entire program of cholesterol and fatty acid biosynthesis by activating transcription of multiple genes encoding enzymes of these pathways (Brown and Goldstein 1997). In the cholesterol biosynthetic pathway, the documented direct targets of nSREBPs include 3-hydroxy-3-methylglutaryl coenzyme A [HMG CoA] synthase, HMG CoA reductase, farnesyl diphosphate synthase, and squalene synthase. Targets in the fatty acid biosynthetic pathway include acetyl CoA carboxylase and fatty acid synthase. In addition, the nSREBPs activate transcription of the low-density lipoprotein (LDL) receptor, which mediates the uptake of cholesterol and fatty acids from plasma (Brown and Goldstein 1997), and glycerol-3-phosphate acyltransferase, which initiates the synthesis of triglycerides (Ericsson et al. 1997). Expression of many other genes is elevated in cells that overexpress the nSREBPs, but it is not known whether these are direct targets of nSREBP action, or whether they are activated secondarily to the activation of other genes. The genes in this category include steroyl CoA desaturase and lipoprotein lipase, among others (for review, see Brown and Goldstein 1997).

Three isoforms of SREBPs have been identified in human and animal cells. SREBP-1a and SREBP-1c are encoded by a single gene (Yokoyama et al. 1993; Hua et al. 1995). They differ in the first exon, which encodes an acidic transcriptional activating domain. SREBP-1a has a longer activation domain, and it is much more potent than SREBP-1c in activating transcription in all cells studied to date (Shimano et al. 1997; Shimomura et al. 1997b). The third isoform of SREBP, designated SREBP-2, is produced by a different gene, and it contains a long acidic-activating domain resembling that of SREBP-1a (Hua et al. 1993). In general, all three SREBPs are capable of activating the same families of genes, but they do so with varying relative efficiencies. SREBP-2 preferentially favors the activation of the cholesterol biosynthetic pathway, whereas SREBP-1a and SREBP-1c tend to favor the fatty acid biosynthetic pathway (Horton et al. 1998; Pai et al. 1998).

The relative amounts of the SREBP-1a and SREBP-1c transcripts differ among cells and organs. SREBP-1a is the predominant transcript in growing cells, such as those in tissue culture. In the body of adult animals, the SREBP-1c transcript predominates in most organs, including liver and adipose tissue (Shimomura et al. 1997b).

In all animal cells, the SREBPs fulfill a crucial housekeeping function in regulating the lipid composition of membranes. In organs that are specialized for lipid metabolism, that is, liver and adipose tissue, the SREBPs play additional roles. In cultured adipose tissue cells, SREBP function has been studied most extensively by Kim and Spiegelman (1996), who focused on the ADD1/SREBP-1c isoform. When the 3T3-L1 line of preadipocytes was transfected with truncated SREBP-1c in 3T3-L1 cells, the amount of lipid accumulation was enhanced (Kim and Spiegelman 1996). In part, this was the result of the ability of nSREBP-1c to induce transcription of genes involved in fatty acid synthesis. Truncated nSREBP-1c also increased the production of an unidentified lipid ligand for peroxisome proliferator activator receptor-γ (PPARγ), a known activator of adipocyte differentiation (Kim et al. 1998b). In response, there was increased transcription of adipocyte-specific genes, such as the fatty acid-binding protein aP2, adipin, and lipoprotein lipase.

The function of nSREBPs has been studied in vivo in transgenic mice (Shimano et al. 1996 and 1997a; Horton et al. 1998). For these studies, the phosphoenolpyruvate carboxykinase (PEPCK) promoter was used to overexpress truncated dominant-positive nSREBPs that lack a membrane attachment domain and therefore enter the nucleus without a requirement for the regulated proteolytic step. When nSREBP-1a was expressed in this fashion, the livers of these animals overproduced cholesterol and triglyceride, and this led to a massive buildup of these lipids in this organ (Shimano et al. 1996). Paradoxically, the mass of triglyceride in white adipose tissue (WAT) declined even though the nSREBP-1a transgene was expressed at high levels in this organ. A similar experiment performed with nSREBP-1c led to a lesser accumulation of triglyceride in the liver, and there was no involution of adipose tissue (Shimano et al. 1997a). In SREBP-1 knockout mice (lacking both SREBP-1a and SREBP-1c), adipose tissue appeared normal, but the interpretation of this finding is unclear because there was a compensatory increase in SREBP-2 expression, which might have replaced the function of SREBP-1 (Shimano et al. 1997b). The SREBP-2 knockout is an embryonic lethal (J. Horton, H. Shimano, M.S. Brown, and J.L. Goldstein, unpubl.).

To further explore the potential role of SREBPs in adipose tissue, in the current studies we produced transgenic mice that express dominant-positive nSREBP-1c in white and brown fat through use of the well-character-
ized adipocyte-specific aP2 enhancer/promoter (Ross et al. 1990). The transgenic mice displayed a syndrome that shares general features with CGL in humans (Seip and Trygstad 1996). The amount of WAT was markedly reduced, and the residual cells had an immature histologic appearance. This was associated with a marked reduction in most mRNAs that are normally abundant in WAT. The brown adipose tissue (BAT) of these animals was enlarged and converted to an appearance that resembled immature WAT. These findings were accompanied by a large fatty liver, profound insulin resistance, and hyperglycemia. These transgenic animals create a new model for the study of defects in adipose tissue development and function in mice.

Results

To achieve unregulated overexpression of nSREBP-1c in adipose tissue, we prepared a transgene encoding amino acids 1–436 of human SREBP-1c driven by a 5.4-kb DNA fragment containing the adipose-specific enhancer/promoter of the gene encoding aP2 (Ross et al. 1990). The truncated SREBP-1c lacks the membrane-attachment domain, and, therefore, it enters the nucleus directly without a requirement for proteolysis. We studied two lines of transgenic mice that were derived from independent founders. Northern blot analysis showed that WAT from line A mice contained approximately twofold more transgene-derived mRNA than did the line B mice (data not shown).

To eliminate any biological effects that might occur simply as a consequence of litters being born to diabetic transgenic females (see below), we propagated all lines through transgenic males. All of the transgenic animals used for the study were hemizygous for the transgene. Litters were of normal size at birth, and transgenic and control mice were indistinguishable. During the first week of life, transgenic mice could be identified on the basis of distended abdomens, bilobed interscapular humps, and runting. Transgenic pups actively nursed and consumed milk as evidenced by visual inspection, but some of the transgenic pups failed to thrive and died. The mortality of transgenic pups during the first 3 weeks of life was ~20% for line A and <5% for line B. Once the transgenic mice began consuming chow, most of them gained weight, and by 40 days of age their weight was similar to that of control littermates. A minority of the transgenic mice remained undersized throughout life.

Gross changes in fat and liver of aP2–SREBP-1c transgenic mice

Figure 1A shows a picture of an aP2–SREBP-1c transgenic mouse (line A) and a wild-type littermate at 7 days of age. In addition to its slightly runted appearance, the transgenic mouse shows a large mass in the interscapular region. A similar mass was present in all transgenic mice. On dissection, the mass was found to be composed of an enlarged bilobed, pale-appearing fat pad in the location where brown fat is usually found (Fig. 1B). The submandibular brown fat depot was also enlarged and pale in the transgenic mice. There was little omental or subcutaneous white fat in either wild-type or transgenic mice at this young age. The livers of the 7-day-old transgenic mice were massively enlarged and very pale, suggesting deposition of fat (Fig. 1C). Transgenic mice that survived the suckling period gradually gained weight and appeared normal except for the abdomen, which remained distended as a result of marked enlargement of the liver. At no time did the animals appear obese, and their body weights were not significantly different from nontransgenic littermates (see Table 1). The interscapular fat depot remained enlarged, but it did not become larger with age.

At 7–12 weeks of age, the transgenic mice showed marked enlargement of the liver, spleen, pancreas, and abdominal lymph nodes. No enlargement of the kidneys, heart, or skeletal muscles was noted. The omental fat, which was readily visible in wild-type littermates, was much smaller in the transgenic mice. Figure 2 shows the enlarged liver of a typical transgenic mouse (line A) at 12 weeks of age. The liver weighed twice as much as that of the wild type; it continued to be pale in appearance. In the wild-type mouse, the interscapular fat pad had the typical amber color of BAT. In the transgenic mouse, the bilobed interscapular fat pad was markedly enlarged, very firm, and white. On the other hand, the WAT of the transgenic mouse, as exemplified by the epididymal fat pad, was atrophic, and it weighed only ~35% as much as the wild-type fat pad. The spleen, pancreas, and abdominal lymph nodes of the transgenic mice (line A) weighed 1.5- to 2-fold more than the corresponding organs of littermate control mice.

Histological changes in fat and liver of 8-day-old transgenic mice

Histologic analysis of organs from 8-day-old mice re-
revealed the following alterations (Fig. 3). In the liver of a transgenic mouse (line A), the hepatocytes were swollen (Fig. 3B). The nuclei remained in the center of the cells, but the cytoplasm stained palely eosinophilic and contained numerous microvesicular vacuoles which, in rare hepatocytes, coalesced to form a distinct unilocular vacuole displacing the nucleus peripherally. The vacuolar change was uniform throughout the hepatic lobule. A similar histologic picture was seen in transgenic mice from line B (data not shown). The epididymal fat pad of an 8-day-old wild-type mouse contained a heterogeneous population of cells consisting of small, immature adipocytes (Fig. 3C, left) and mature adipocytes, each of which contained a large unilocular vacuole (Fig. 3C, right). In contrast, the white epididymal fat of the transgenic mouse consisted almost entirely of small immature adipocytes with brightly eosinophilic cytoplasm and a distinct unilocular vacuole (Fig. 3D). The cytoplasm of brown adipocytes from the transgenic mouse contained large unilocular vacuoles similar to those of immature white adipocytes (Fig. 3F) in contrast to the small multi-

Table 1. Phenotypic comparison of wild-type and transgenic aP2-SREBP-1c436 mice

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Line A (7 weeks old)</th>
<th>Line B (11 weeks old)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>wild type</td>
<td>transgenic</td>
</tr>
<tr>
<td></td>
<td>3 M, 4 F</td>
<td>3 M, 4 F</td>
</tr>
<tr>
<td>Body weight (grams)</td>
<td>20.7 ± 1.0</td>
<td>18.9 ± 0.8</td>
</tr>
<tr>
<td>Liver weight (grams)</td>
<td>1.3 ± 0.09</td>
<td>2.4 ± 0.11</td>
</tr>
<tr>
<td>Liver weight/body weight (%)</td>
<td>5.9 ± 0.30</td>
<td>12.7 ± 0.41</td>
</tr>
<tr>
<td>Liver weight/body weight (%)</td>
<td>0.22 ± 0.01</td>
<td>0.064 ± 0.003</td>
</tr>
<tr>
<td>Epididymal fat/body weight (%)</td>
<td>1.01 ± 0.005</td>
<td>0.37 ± 0.04</td>
</tr>
<tr>
<td>Brown fat weight (grams)</td>
<td>0.027 ± 0.002</td>
<td>0.100 ± 0.017</td>
</tr>
<tr>
<td>Brown fat/body weight (%)</td>
<td>0.13 ± 0.01</td>
<td>0.51 ± 0.09</td>
</tr>
<tr>
<td>Liver cholesterol content (mg/gram)</td>
<td>2.7 ± 0.13</td>
<td>4.6 ± 0.94</td>
</tr>
<tr>
<td>Liver triglyceride content (mg/gram)</td>
<td>7.9 ± 0.42</td>
<td>113 ± 12.4</td>
</tr>
<tr>
<td>Plasma FFA (µM)</td>
<td>771 ± 89</td>
<td>810 ± 162</td>
</tr>
<tr>
<td>Total plasma cholesterol (mg/dl)</td>
<td>91 ± 3.3</td>
<td>148 ± 8.2</td>
</tr>
<tr>
<td>Brown fat weight (grams)</td>
<td>0.027 ± 0.002</td>
<td>0.100 ± 0.017</td>
</tr>
<tr>
<td>Total plasma triglycerides (mg/dl)</td>
<td>74 ± 1.9</td>
<td>112 ± 8.2</td>
</tr>
</tbody>
</table>

Each value represents the mean ± S.E.M. of the indicated number of mice. Wild-type mice were littermates of the transgenic mice. Values in parentheses denote the level of statistical significance (Student’s t-test): (*P < 0.05; †P < 0.01; ‡P < 0.001.

a(M) Male; (F) female.

Figure 2. Liver, interscapular brown fat, epididymal white fat/testis from a 3-month-old wild-type male mouse (left) and a transgenic aP2-SREBP-1c436 [line A] male littermate mouse (right). The wild-type and transgenic livers weighed 1.5 and 3.9 grams, respectively. The wild-type and transgenic interscapular fat weighed 58 and 110 mg, respectively. The wild-type and transgenic epididymal fat weighed 510 and 160 mg, respectively.

Figure 3. Histologic sections of liver (A,B), white fat (C,D), and brown fat (E,F) from an 8-day-old wild-type male mouse and a transgenic aP2-SREBP-1c436 male littermate mouse (hematoxylin and eosin stain, magnification, 112 ×). (A,B) Hepatocytes throughout the liver of the transgenic mouse are dramatically swollen. The cytoplasm stains palely eosinophilic and contains numerous microvesicular vacuoles. The alteration is uniform throughout the lobules. Scattered hematopoietic foci are present in both the wild-type and transgenic liver. (C) White fat pad of a wild-type mouse contains a heterogeneous population of cells consisting of both small immature adipocytes (left) and mature adipocytes, each of which contains a large unilocular vacuole (right). (D) White fat of the transgenic mouse contains numerous, small immature adipocytes with brightly eosinophilic cytoplasm and a distinct unilocular vacuole. (E,F) Adipocytes of the brown fat of the transgenic mouse are dramatically enlarged and stain palely. The cytoplasm is replaced by numerous small vacuoles that frequently coalesce to form large unilocular vacuoles, resembling those of immature white adipocytes.
lygonal, multilocular adipocytes that were organized into lobules separated by connective tissue stroma (Fig. 4E). In contrast, the majority of adipocytes in brown fat of the transgenic mice were markedly enlarged and contained a prominent unilocular fat droplet (Fig. 4F). Small numbers of immature adipocytes were scattered throughout the sections. The brown fat pads showed a proliferation of pericellular and interlobular connective tissue both surrounding the cells and within the septa, and there was evidence of mild inflammation (Fig. 4F).

Comparison of metabolic parameters in wild-type and transgenic mice

Table 1 compares relevant quantitative parameters in wild-type mice and littermates from transgenic lines A and B. In general, the changes in the line B mice were in the same direction as the line A animals, but they were less profound. The body weights of the transgenic mice were normal, but the livers were significantly enlarged. The epididymal fat pads were small, and the interscapular brown fat was large. The hepatic content of triglyceride was markedly elevated. Hepatic cholesterol content was mildly increased, although the values did not reach statistical significance. Despite the marked fatty liver in 7-week-old line A mice, the plasma levels of albumin, aspartate aminotransferase, and bilirubin were normal [data not shown]. The level of free fatty acids in the fed state were normal (Table 1). The plasma levels of cholesterol and triglycerides were mildly, but significantly elevated in the line A mice (7 weeks old), and there was a similar trend in line B [11 weeks old]. In data not shown in Table 1, we studied four line A mice that were 9–11 months of age. The plasma triglyceride levels were markedly elevated (mean of 450 mg/dl; range, 367–565) when compared with five littermate controls (mean of 97 mg/dl; range, 75–147).

Expression of mRNAs for target genes in fat and liver

Blot-hybridization analysis of mRNA in the line A mice confirmed that the transgene was expressed in white and brown fat, but not in the liver (Fig. 5A). We also found no evidence of expression of the transgene in other tissues, including spleen, pancreas, and skeletal muscle [data not shown]. In wild-type mice, immunoblots of nuclear extracts showed trace amounts of nSREBP-1a or nSREBP-1c in both white and brown fat. In contrast, nuclear extracts from white and brown fat of the line A transgenic mice showed abundant nSREBP-1c, which appeared to be manyfold above normal for these tissues. For comparative purposes, we estimate that the amount of nSREBP-1c in adipose tissue nuclei in the transgenic mice was approximately twofold higher than the level in nuclei from livers of wild-type mice. The level of expression of nSREBP-1c in white and brown fat of line B mice was approximately one-half of that in line A mice [data not shown].

White and brown fat of the line A transgenic mice...
showed massive increases in the mRNA encoding the LDL receptor (11- and 12-fold, respectively) [Fig. 5A]. Similar elevations were seen in the mRNA encoding HMG CoA reductase. The mRNA for HMG CoA synthase, another target of SREBPs, was elevated only in white fat and only by 2.9-fold. In wild-type mice, the mRNAs of the fatty acid biosynthetic pathway (fatty acid synthase, acetyl CoA carboxylase, and stearoyl CoA desaturase) were much lower in brown fat than in white fat. The aP2–SREBP-1c436 transgene abolished this discrepancy, raising these mRNAs selectively in brown fat so that they became equal to the levels in white fat.

Even though the transgene was not expressed in liver, the livers of the transgenic mice showed a marked increase in the mRNA encoding fatty acid synthase [6.4-fold] and significant increases in mRNAs encoding acetyl CoA carboxylase mRNA [2.4-fold] and stearoyl CoA desaturase [4.2-fold] [Fig. 5A]. The other mRNA changes were all less than twofold. The possible reason for the increased mRNAs for fatty acid biosynthetic enzymes is discussed below.

Figure 5B shows a more extensive analysis of mRNA expression in white and brown fat of wild-type mice and their transgenic aP2–SREBP-1c436 littermates. Both fat depots of transgenic animals exhibited profound reductions in three mRNAs that are associated with fully differentiated adipocytes, that is, PPARγ, C/EBPα, and adipsin. In wild-type mice, the amount of leptin mRNA was much higher in white fat than in brown fat. The transgenic animals exhibited a 90% reduction in leptin mRNA in white fat and a 50% reduction in the already low levels in brown fat. The expression of aP2 was reduced by ~50% in both fat depots. In wild-type mice, the mRNA for uncoupling protein 1 (UCP1) was detectable only in BAT. This mRNA was reduced by >95% to undetectable levels in the brown fat of the transgenic mice. White and brown fat showed profound 70%–90% reductions in four mRNAs that encode proteins that play roles...
in insulin action, that is, the insulin receptor, IRS-1, IRS-2, and glucose transporter-4 (GLUT4). The mRNA for endogenous SREBP-1 was elevated approximately two-fold in white and brown fat of the transgenic mice, but there was no change in the mRNA for SREBP-2.

Two conspicuous mRNAs were elevated in white and BAT of transgenic mice, namely tumor necrosis factor-α (TNFa) and Pref-1 [Fig. 6]. Pref-1 is a cell surface molecule with epidermal growth factor repeats whose overexpression inhibits the terminal differentiation of adipocytes in tissue culture [Smas and Sul 1993]. TNFa mRNA was not elevated in muscle, liver, or spleen of the transgenic mice.

Measurements of plasma glucose, plasma insulin, and insulin sensitivity

Nonfasting plasma insulin levels were elevated by 60-fold in line A transgenic mice and 22-fold in line B [Fig. 7A,C]. In the line A transgenic mice, the blood sugar was markedly elevated (mean value 305 mg/dl), but was not significantly elevated in the line B animals (Fig. 7B,D). In other experiments, we did observe elevated blood glucose levels in the line B animals [see legend to Fig. 8]. Insulin tolerance tests showed that mice from line A and line B were markedly resistant to the glucose-lowering effect of exogenous insulin [Fig. 8]. To date, we have studied 43 transgenic mice from lines A and B, and all have had insulin resistance as determined by measurement of plasma insulin levels or insulin tolerance tests.

To determine whether skeletal muscle from the transgenic mice was resistant to insulin in vitro, we excised the soleus muscles from line A mice and wild-type littermates and incubated them with [3H]2-deoxyglucose in the absence or presence of insulin (10 nM or 100 nM) [Fig. 9]. Insulin at both concentrations stimulated the uptake of [3H]2-deoxyglucose equally in both types of mouse.

Discussion

Transgenic mice that overexpress nSREBP-1c in adipose tissue exhibit a distinct syndrome with five prominent features: paucity of white fat and signs of disordered differentiation; hypertrophic brown fat that assumes the appearance of immature white fat; massive fatty liver; insulin resistance; and diabetes mellitus. In contrast to all other mouse models of insulin resistance [Spiegelman et al. 1993; Spiegelman and Flier 1996], the aP2–SREBP-1c transgenic mice were not obese. Rather, the phenotype appeared more analogous to human CGL (Seip and Trygstad 1996).

Disordered differentiation of white fat

At 8 days of age, even in wild-type mice, white fat was scanty and appeared immature. The appearance was similar in the transgenic littermates. By 6 weeks of age, the white fat of the wild-type animals had developed its normal mature appearance [Slavin 1979; Hausman and Richardson 1983]. In contrast, the white fat of the 40-
day-old transgenic mice continued to resemble the immature tissue that was seen at day 8. The block in differentiation of WAT was not complete. On careful histologic examination, the epididymal fat pads of most transgenic animals contained islands of normal-appearing WAT. The weight of the epididymal fat pads was only 30%–40% of normal, and there was visual evidence for reduction of other white fat depots including omental and perinephric fat.

In the transgenic mice, the immature state of the WAT was reflected by the increased expression of the mRNA for Pref-1. This mRNA was cloned originally from cultured 3T3-L1 mouse preadipocytes on the basis of its differential expression in immature, but not mature, cells [Smas and Sul 1993]. The current data show that Pref-1 is present at low, but detectable, levels in epididymal fat pads of C57BL/6J × SJL strain mice at 7 weeks of age, and its level was elevated by fourfold in the transgenic mice. This was accompanied by a decline in many of the mRNAs that are usually found in mature adipose tissue. The decline was most marked for adipsin, which became undetectable [Fig. 5B]. There were also major declines in mRNAs encoding PPARγ, C/EBPα, and leptin, but a somewhat surprising persistence of the mRNA for aP2, which declined by only 50%. This was fortuitous, because expression of the transgene was driven by the aP2 promoter, and the transgene would have been extinguished if transcription of this gene had been turned off.

The action of nSREBP-1c in blocking differentiation of adipocytes in mice appears to differ from its action in cultured mouse 3T3-L1 preadipocytes in which it increases adipocyte differentiation. This action is responsible for its alternative name, ADD1 [Tontonoz et al. 1993; Kim and Spiegelman 1996]. Increased differentiation in tissue culture is believed to result, in part, from an SREBP-induced increase in the production of an activating ligand for PPARγ, most likely a lipid [Kim et al. 1998b]. Other activators of PPARγ, such as thiazolidinediones, are known to enhance adipocyte differentiation [Spiegelman and Flier 1996]. In adipose tissue of transgenic mice, the overexpression of nSREBP-1c paradoxically lowers the amount of mRNA encoding PPARγ, along with other markers of adipocyte differentiation. It is possible that the differences between the in vivo and in vitro response relates to the stage of differentiation in which nuclear SREBP-1c is expressed.

**Disordered differentiation of brown fat**

The metabolic events underlying the development of BAT have not yet been elucidated either in vivo or in vitro. The current data suggest that it is possible to convert BAT into something resembling immature WAT by the forced overexpression of nSREBP-1c.

In normal mice, brown fat differentiates during embryonic development, whereas white fat completes its differentiation postnatally [Slavin 1979]. At the time of birth, nSREBP-1c overexpression had already caused massive enlargement of brown fat depots. By 8 days of age, histologic studies showed that the brown fat depot contained markedly enlarged, fat-filled adipocytes.
There was a complete disappearance of the mRNA for UCP1, the major differentiation marker of BAT (Fig. 5B). The mRNA for adipin, normally found in mature brown and white fat, became undetectable in both fat tissues of the transgenic mice (Fig. 5B). In the brown fat of the transgenic mice, the mRNAs encoding enzymes of fatty acid synthesis rose so that the profile resembled that of the WAT in the same animals (Fig. 5A). The mRNA for Pref-1, a marker of immature WAT, rose by fourfold in the BAT depots of the transgenic mice (Fig. 6).

Fatty liver

The livers of the transgenic mice were overloaded with fat as early as 8 days of age. The mechanism for this fatty liver is almost certainly indirect. The aP2 enhancer/promoter does not support expression in liver (Ross et al. 1990), and we found no evidence of expression of the transgene in this organ. Nevertheless, the levels of mRNA encoding acetyl CoA carboxylase, fatty acid synthase, and stearoyl CoA desaturase were all elevated in liver despite a massive accumulation of triglyceride. The levels of plasma-free fatty acids were not elevated in the transgenic mice, suggesting that the loss of function of BAT cannot be the complete explanation for the aP2–SREBP-1c phenotype. First, in the BAT-ablated animals, insulin resistance developed gradually during life in parallel with progressive obesity. At 6 weeks of age, insulin levels in the BAT-ablated mice were not markedly elevated, but they became massively elevated at 22–26 weeks, at which time the animals were definitely obese. The livers were not noted to be markedly enlarged or fatty. In contrast, in the aP2–SREBP-1c transgenics insulin resistance was massive at 6 weeks in the absence of obesity, and the liver was fatty as early as 8 days.

Relation between human CGL and lipodystrophy in aP2–nSREBP-1c transgenic mice

The syndrome observed in the aP2–nSREBP-transgenic mice resembles some, but not all, of the features of human CGL (Seip and Trygstad 1996). Common aspects include disordered differentiation of WAT, profound insulin resistance, hyperglycemia, enlarged fatty liver, hypertriglyceridemia, and increased size of certain organs, including the pancreas and spleen. The block in differentiation of WAT is not as profound in the mice, as it is in the human disease, in which WAT is barely detectable. In affected humans and mice, the plasma levels of free fatty acids tend to be normal, and the individuals fail to develop ketoacidosis despite profound insulin resistance.

The most prominent difference between humans with CGL and the aP2–nSREBP-1c transgenic mice relates to the absence of a hypertrophic interscapular fat pad in the human disease. This may be attributable to the fact that humans seem to lack distinct brown fat depots analogous to the interscapular brown fat pad in mice, at least in adulthood (for review, see Foster 1992). Even in humans with CGL, some fat depots are spared. Studies by Garg et al. (1992) showed that certain fat depots are preserved in humans with CGL, including the palms, soles, tongue, breasts, and periarticular regions. These may have some analogy with the preserved interscapular fat depots in the aP2–nSREBP-1c transgenic animals.

The aP2–nSREBP-1c transgenic mice also fail to show the acceleration of linear growth or the hypertrophic cardiomyopathy that develops in some humans with CGL. The latter observation may relate to the relatively short period of observation of the mice. The oldest mice are 9–11 months of age. Further studies of the hearts of aging aP2–nSREBP-1c transgenic mice are planned.

Underlying mechanism in the aP2–nSREBP-1c transgenic mice

The mechanism by which overexpression of nSREBP-1c in adipose tissue interferes with adipocyte differentiation and causes insulin resistance remains to be elucidated. The most straightforward scenario postulates that nSREBP-1c increases the expression of antiderivative-
tion factors such as Pref-1 and decreases the expression of prodifferentiation proteins such as C/EBPα and PPARγ. Whether this is a direct effect of nSREBP-1c acting on these promoters, or whether it is secondary to the action of nSREBP-1c on other promoters, remains to be determined. The nSREBP-1c seems clearly to stimulate several SREBP-responsive promoters. The amount of LDL receptor mRNA was elevated by >10-fold in both white and brown fat and a similar elevation was seen in the mRNA for HMG CoA reductase. Yet, another SREBP-driven mRNA, HMG CoA synthase, was elevated only modestly. The transcriptional activity of nSREBP-1c must be highly dependent on other factors that allow it to selectively activate only a subset of SRE-containing promoters.

It is also possible that nSREBP-1c is disturbing adipocyte differentiation by acting negatively to block transcription of one or more key genes. This possibility arises because nSREBP-1c is a much less potent activator of transcription than is nSREBP-1a or nSREBP-2 (Shimano et al. 1997a; Pai et al. 1998). The aP2–nSREBP-1c transgene encodes a truncated version of SREBP-1c that enters the nucleus directly without a requirement for proteolysis. Hence, it is immune to the process of feedback regulation that limits the amount of nSREBP-1c in the nucleus of normal cells. Our immunoblots reveal that the amount of nSREBP-1c in adipose tissue nuclei of the transgenic mice is orders of magnitude higher than the amount that is normally in the nucleus of adipocytes. At such high levels, nSREBP-1c might form partially active heterodimers with nSREBP-1a or nSREBP-2, thereby limiting their activities. It also might bind indiscriminately to a subset of sterol regulatory elements or E boxes, thereby precluding access by more potent transcription factors.

Many of the hypotheses outlined above are susceptible to testing either in the transgenic mice or in tissue culture experiments. If the link can be found between nSREBP-1c overexpression and disordered adipose tissue differentiation, it might help us to understand not only CGL, but also other states of insulin resistance in humans such as noninsulin-dependent diabetes mellitus. It might also increase our understanding of the recently reported syndrome of lipodystrophy, insulin resistance, and hyperlipidemia that occurs in AIDS patients who are treated with inhibitors of the HIV protease (Carr et al. 1998; Viraben and Aquilina 1998).

Related but distinct form of lipodystrophy

Burant et al. (1997) recently described a delayed-onset form of lipodystrophy that arose when the adipose tissue of the mouse was genetically ablated by the targeted expression of a diphertheria toxin A transgene under control of the aP2 enhancer/promoter [aP2–DT mice]. In contrast to the currently studied aP2–nSREBP-1c transgenic mice, the aP2-DT mice were phenotypically normal at birth (Ross et al. 1993) and showed no signs of lipodystrophy until 5–6 months of age, at which time the adipose tissue began to disappear (Burant et al. 1997). By 8–10 months of age, at a time when no WAT was visible, the animals showed the cardinal features of lipodystrophy, including insulin resistance, diabetes, fatty liver, and hypertriglyceridemia. Remarkably, oral treatment of the mice with troglitazone, a potent activator of PPARγ in adipose tissue (Spiegelman and Flier 1996), improved the hyperglycemia and normalized the insulin resistance even though the animals had no detectable adipose tissue (Burant et al. 1998). Whether or not the congenital lipodystrophy in the aP2–nSREBP-1c transgene mice will respond to troglitazone remains to be determined.

Materials and methods

Assays and procedures

The content of cholesterol and triglycerides in plasma and liver was measured as described (Yokode et al. 1990; Ishibashi et al. 1993). Plasma insulin levels were measured with a monoclonal anti-rat insulin radioimmunooassay by use of the Rat Insulin RIA Kit (Linco Research, St. Charles, MO). The measurements in Figures 7C and 8 were made in the authors’ laboratory and those in Figure 7A by Ani Lytics (Gaithersburg, MD). Plasma glucose levels in Figures 7D and 8 were measured in the authors’ laboratory by use of the Glucose (Trinder) 100 Kit (Sigma Diagnostics, St. Louis, MO). Plasma glucose measurements in Figure 7B were carried out by Ani Lytics with the Glucose/HK Kit (Boehringer Mannheim, Indianapolis, IN). Plasma-free fatty acids were measured by Ani Lytics with the Wako NEFA C Test Kit (Wako Chemicals, Richmond, VA). Sequencing reactions were performed on an Applied Biosystem model 373A DNA sequencer by the dideoxy chain termination method (Sambrook et al. 1989). For histological studies, the tissues were harvested, fixed in 10% (vol/vol) buffered formalin, dehydrated through graded ethanols, and embedded in paraffin. Sections were cut at 4 μm and stained with hematoxylin and cosin. 2-[3H]deoxy-d-glucose (10 Ci/mmol) and d-[1-14C]mannitol (55 mCi/mmol) were obtained from American Radiolabeled Chemicals (St. Louis, MO). Human crystalline insulin was obtained from Lilly (Indianapolis, IN).

Plasmid constructions

An expression plasmid containing the mouse aP2 promoter/enhancer (Ross et al. 1990) upstream of the sequences encoding amino acids 1–436 of human SREBP-1c (Shimano et al. 1997a) was constructed in three steps as follows. A 1.4-kb SalI fragment that encodes amino acids 1–436 of human SREBP-1c was excised from pPEPCK–SREBP-1c (Shimano et al. 1997a) and ligated into the SalI site of pCMV7 (Yokoyama et al. 1993), which contains a polyadenylation signal from the human growth hormone cDNA. A 1.7-kb SalI–SphI fragment encoding amino acids 1–436 of human SREBP-1c followed by the 3′ polyadenylation signal was excised from the above plasmid, and the ends were filled in by DNA polymerase I (Klenow fragment). The resulting fragment was subcloned into the Smal site of a pBluescript II SK(+) vector containing the 5.4-kb promoter/enhancer of the mouse aP2 gene (kindly provided by Dr. Bruce M. Spiegelman; Ross et al. 1990). The final plasmid is designated pA2–SREBP-1c436. The integrity of the plasmid was confirmed by DNA sequencing of the ligation junctions.

Transgenic mice

The technique used for generating transgenic mice has been

Mouse model for human lipodystrophy
described previously (Yokode et al. 1990). A 7.1-kb Noti–ClaI fragment of paP2–SREBP-1c436 was purified on a SeaKem GTG agarose gel (FMC Bioproducts, Rockland, ME) prior to microinjection into fertilized eggs from the C57BL/6J × SJL F2 strain of mice. A total of 452 fertilized eggs that were microinjected with the Not1–ClaI fragment of paP2–SREBP-1c436 survived to the two-cell stage. Among the 52 offspring, 11 (19%) had integrated the transgene as determined by dot blot hybridization of DNA from tail homogenates. These 11 founder mice were subjected to partial adipectomy, and 82% produced the human SREBP-1c436 transcript as determined by Northern blotting analysis. Mixed with high levels of transgene expression were bred to C57BL/6J × SJL F1 mice, and two independently derived lines of transgenic mice, transgenic aP2–SREBP-1c436 (A and B), were established and characterized.

Mice were housed in colony cages and maintained on a 14-hr light/10-hr dark cycle. Transgenic and nontransgenic littermate mice were fed Teklad 4% Mouse/Rat Diet no. 7001 from Harlan Teklad Premier Laboratory Diets (Madison, WI).

**Blot hybridization of RNA**

Plasmids containing sequences encoding mouse C/EBPβ and C/EBPα were obtained from Steven McKnight (Cao et al. 1991). A plasmid encoding mouse PPARY was obtained from Ronald Evans (Kliewer et al. 1994). A plasmid-encoding mouse UCP1 was obtained from Leslie Kozak (Kozak et al. 1988). A plasmid-encoding mouse IRS-2 was obtained from Morris White (Evans (Kliewer et al. 1994). A plasmid-encoding mouse C/EBPβ was established and characterized.

Mice with high levels of transgene expression were bred to C57BL/6J × SJL F1 mice, and two independently derived lines of transgenic mice, transgenic aP2–SREBP-1c436 (A and B), were established and characterized.

**Insulin tolerance test**

Insulin tolerance tests were performed on fed 12-week-old (line A) and 14-week-old (line B) mice. Animals were injected intraperitoneally with 0.75 U/kg body weight (~900 ng per mouse) of human insulin. Blood was taken by retro-orbital puncture immediately thereafter at 5, 15, and 30 min after injection for measurement of plasma glucose levels.

**Glucose uptake in isolated muscle**

Glucose uptake into isolated soleus muscle was measured by a modification of the method of Hansen et al. (1994). Nonfasted mice were killed by cervical dislocation, and both soleus muscles were rapidly removed and tied to stainless-steel clips by the tendons. Left and right muscles were used for measurement of basal and insulin-stimulated uptake of glucose, respectively. Incubations were carried out at 35°C with continuous shaking under an atmosphere of 95% O2 and 5% CO2 in Krebs–Ringer bicarbonate buffer at pH 7.4 containing 0.1% (gram/vol) BSA, and 2 mM sodium pyruvate (KRBB buffer). The soleus muscles were preincubated for 40 min in KRBB buffer supplemented with 8 mM glucose and 32 mM mannitol to stabilize muscle metabolism. The muscles in each group were then sequentially incubated for 20 min with or without 10 or 100 nM human insulin; washed for 10 min with glucose-free KRBB buffer supplemented with 40 mM mannitol with or without insulin; incubated for 15 min with KRBB buffer supplemented with 1 mM [3H]2-deoxyglucose (2064 or 2200 Ci/m mole).

**RNase protection assay**

cDNA fragments for mouse preadipocyte factor 1 (Pref-1) and mouse TNFα were amplified by PCR from first-strand cDNA prepared from 3T3-L1 preadipocyte poly(A)+ RNA and mouse spleen 5′-stretch plus cDNA library (Clontech, Palo Alto, CA), respectively, with the following primers. Pref-1: 5′-primer 5′-GCCGCGGCGTGACCCGAGG-3′; and 3′-primer 5′-AAGTGTCGATCGTCAATCTCGAAT-3′ (Smas et al. 1993). TNFα, 5′-primer 5′-GCATGATCCGCGACGTGGAACTGGC-3′; and 3′-primer 5′-GCTCAGCCACTCAGCCTGGA-3′ (Caput et al. 1986). The 5′ and 3′ primers were added with HindIII and EcoRI sites, respectively. First-strand cDNA was prepared by use of a SuperscriptII kit (GIBCO-BRL).

Amplified cDNA fragments were subcloned into the pGEM-3ZI(+)-vector (Promega). After linearization of plasmid DNA with HindIII, antisense RNA was transcribed with [α-32P]CTP (800 Ci/m mole) by use of bacteriophage T7 RNA polymerase (Ambion, Austin, TX). Specific activities of the transcribed RNAs were measured in each experiment and were in the range of 1.7–2.6 × 106 cpm/µg for all RNAs except for β-actin RNA, which was 5.3–8.1 × 106 cpm/µg.

Aliquots of total RNA (20 µg) from each sample were subjected to the RNase protection assay with a HybSpeed RPA kit (Ambion, Inc.) as described previously (Shimomura et al. 1997a,b). Each assay tube contained a cRNA probe for the mRNA to be tested plus a cRNA probe complementary to the mRNA of β-actin. In preparing the probes, we adjusted the specific activity of the [α-32P]CTP to give a β-actin signal comparable to the test mRNAs. After digestion of RNase A/T1, protected fragments were separated on 8 m urea/4.8 % polyacrylamide gels, and the gels were dried and subjected to autoradiography by use of reflection film and intensifying screens (Dupont, Wilmington, DE). The dried gels were also analyzed quantitatively with a Fuji PhosphorImager as described above. The level of β-actin mRNA in each RNA sample was used to normalize signals obtained for the test mRNAs.
Acknowlegments

We thank our colleagues Hitoshi Shimano, Jay Horton, Sarah Comerford, Robert O’Doherty, Robert Grange, Michio Shima-bukuro, Denis McGarry, and Roger Unger for helpful discussions and reagents; Richard Gibson, Beth Hinnart, Shan Maika, and Mario Villareal for expert help with the animal studies; Scott Clark, Robin Craddock, and Debra Morgan for excellent technical assistance; and Robert Webb for invaluable assistance with histologic sectioning. This work was supported by grants from the National Institutes of Health (HL-20948), the Moss Heart Foundation, and the Perot Family Foundation. I.S. is the recipient of a Research Fellowship from the Manpei Suzuki Diabetes Foundation of Tokyo, Japan. S.I. is the recipient of a Research Fellowship from The National Institute of Health and Nutrition of Japan.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked ‘advertisement’ in accordance with 18 USC section 1734 solely to indicate this fact.

References


Shimomura et al.


Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy

Iichiro Shimomura, Robert E. Hammer, James A. Richardson, et al.

*Genes Dev.* 1998 12: 3182-3194
Access the most recent version at doi:10.1101/gad.12.20.3182

**References**
This article cites 46 articles, 21 of which can be accessed free at: [http://genesdev.cshlp.org/content/12/20/3182.full.html#ref-list-1](http://genesdev.cshlp.org/content/12/20/3182.full.html#ref-list-1)

**Email Alerting Service**
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](http://genesdev.cshlp.org/subscriptions).